Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(23):1731; doi:10.1093/jnci/94.23.1731-b
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

Journal of the National Cancer Institute, Vol. 94, No. 23, 1731, December 4, 2002
© 2002 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Developing a New Class of Apoptosis-Inducing Agents

The cyclooxygenase-2 (COX-2) inhibitor celecoxib is thought to act as a chemopreventive agent by sensitizing cancer cells to apoptotic signals. Another COX-2 inhibitor, rofecoxib, has the same COX-2 inhibitory potency as celecoxib but is less potent at inducing apoptosis. Zhu et al. (p. 1745) systematically modified the structures of celecoxib and rofecoxib to produce a series of compounds that were tested for their effects on the viability of human prostate cancer PC-3 cells and their ability to induce apoptosis in these cells. They found that the structural requirements for the induction of apoptosis were different . . . [Full Text of this Article]

Tumor and Nontumor EBV Promoter Differences

Sigmoidoscopy Screening Trial: Baseline Results

Oral Contraceptives and Breast Cancer Risk

HLA Alleles and Haplotypes and Nasopharyngeal Carcinoma

Antitumor Activity of Sindbis Viral Vectors